REG - Immupharma PLC - Grant of Share Options & PDMR dealing

ImmuPharmaAnnouncement

26/11/2020 07:00

RNS Number : 5422G
  
Immupharma PLC
  
26 November 2020
  
 




RNS / eCorporate


26 November 2020



 
ImmuPharma PLC
("ImmuPharma" or the "Company")
 
Grant of Share Options & PDMR dealing
 
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to Directors, employees and consultants representing 3.8% of ImmuPharma's Ordinary Shares and total voting rights  (the "Options").  ImmuPharma currently has 250,221,297 Ordinary Shares in issue.
 
Upon the recommendation of the Company's remuneration committee, the Company has granted the Options pursuant to the Company's Share Option Plan which was adopted on 30 March 2017 (the "2017 Plan").
 
The exercise price for the Options is 20p being a 54% premium to the closing middle market share price of 13p on 25 November 2020.  The Options will vest after three years and are exercisable between three and ten years from the date of grant.
 
The amount of Options granted to the Directors are summarised in the following table:
 



Director


Options Granted




Dimitri Dimitriou


1,500,000




Dr Robert Zimmer


1,875,000*




Tim McCarthy


1,500,000




Dr Franco di Muzio


300,000




Dr Stephane Mery


300,000



*Includes 375,000 Options granted to Elizabeth Zimmer, Robert Zimmer's wife who is also an employee of the Company
 
Following the grant of Options, the Directors will have the following interests in share options in the Company:
 



Director


Number of options


Exercise Price


Expiry Date




Dimitri Dimitriou


1,000,000
1,500,000
1,500,000


50.25p
98.62p
20.00p


30.03.2027
24.11.2027
26.11.2030




Dr Robert Zimmer


50,000*
100,000*
1,250,000*
1,875,000*
1,875,000*


90.75p
43.88p
50.25p
98.62p
20.00p


24.11.2021
02.06.2026
30.03.2027
24.11.2027
26.11.2030




Tim McCarthy


500,000
1,000,000
1,500,000
1,500,000


43.88p
56.75p
98.62p
20.00p


02.06.2026
12.07.2027
24.11.2027
26.11.2030




Dr Franco di Muzio


100,000
200,000
300,000
300,000


43.88p
56.75p
98.62p
20.00p


02.06.2026
12.07.2027
24.11.2027
26.11.2030




Dr Stephane Mery


100,000
200,000
300,000
300,000


43.88p
56.75p
98.62p
20.00p


02.06.2026
12.07.2027
24.11.2027
26.11.2030



*Includes Options granted to Elizabeth Zimmer, Robert Zimmer's wife who is also an employee of the Company
 
The Directors currently have the following interests in Ordinary Shares:
 



Director


Number of Ordinary Shares


% of issued share capital at 
25 November 2020




Dimitri Dimitriou


3,567,430


1.45%




Dr Robert Zimmer


27,344,514*


11.10%




Tim McCarthy


38,462


0.01%




Dr Franco di Muzio


99,412


0.04%




Dr Stephane Mery


21,490


0.01%



 
*includes 22,000,000 shares held by Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder.
 
Other grants of Options to Persons Discharging Managerial Responsibilities ("PDMR")
 
1,500,000 Options have been granted to Tim Franklin, Chief Operating Officer of the Company. Following the grant of these Options, Tim Franklin will hold Options over 1,500,000 Ordinary Shares in the Company. Similarly, 375,000 Options have been granted to Ewa Flynn, Financial Controller of the Company. Following the grant of these Options, Ewa Flynn will hold Options over 375,000 Ordinary Shares in the Company. Neither Dr Franklin nor Ewa Flynn currently hold any interests in Ordinary Shares in the Company. 
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Dimitri Dimitriou




2


Reason for the notification




a)


Position/status


Chief Executive Officer




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


Grant of share options over Ordinary Shares




c)
 


Price(s) and volume(s)
 


Price


Volume




Exercise price: 20p per Ordinary Share


1,500,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


N/A




e)


Date of the transaction


25 November 2020




f)


Place of the transaction


Off market



 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Dr Robert Zimmer




2


Reason for the notification




a)


Position/status


President & Chief Scientific Officer




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


Grant of share options over Ordinary Shares




c)
 


Price(s) and volume(s)
 


Price


Volume




Exercise price: 20p per Ordinary Share


1,875,000
(includes 375,000 to Elizabeth Zimmer)




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


N/A




e)


Date of the transaction


25 November 2020




f)


Place of the transaction


Off market



 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Tim McCarthy




2


Reason for the notification




a)


Position/status


Non-Executive Chairman




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


Grant of share options over Ordinary Shares




c)
 


Price(s) and volume(s)
 


Price


Volume




Exercise price: 20p per Ordinary Share


1,500,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


N/A




e)


Date of the transaction


25 November 2020




f)


Place of the transaction


Off market



 
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Dr Franco Di Muzio 




2


Reason for the notification




a)


Position/status


Non-Executive Director




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


Grant of share options over Ordinary Shares




c)
 


Price(s) and volume(s)
 


Price


Volume




Exercise price: 20p per Ordinary Share


300,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


N/A




e)


Date of the transaction


25 November 2020




f)


Place of the transaction


Off market



 
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Dr Stéphane Méry




2


Reason for the notification




a)


Position/status


Non-Executive Director




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


Grant of share options over Ordinary Shares




c)
 


Price(s) and volume(s)
 


Price


Volume




Exercise price: 20p per Ordinary Share


300,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


N/A




e)


Date of the transaction


25 November 2020




f)


Place of the transaction


Off market



 
PDMR Options
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Dr Tim Franklin




2


Reason for the notification




a)


Position/status


Chief Operating Officer




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


Grant of share options over Ordinary Shares




c)
 


Price(s) and volume(s)
 


Price


Volume




Exercise price: 20p per Ordinary Share


1,500,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


N/A




e)


Date of the transaction


25 November 2020




f)


Place of the transaction


Off market



 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Ewa Flynn




2


Reason for the notification




a)


Position/status


Financial Controller




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


Grant of share options over Ordinary Shares




c)
 


Price(s) and volume(s)
 


Price


Volume




Exercise price: 20p per Ordinary Share


375,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


N/A




e)


Date of the transaction


25 November 2020




f)


Place of the transaction


Off market



 
 
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
 

 



For further information please contact:
 



ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman


+ 44 (0) 207 152 4080




Dimitri Dimitriou, Chief Executive Officer








Lisa Baderoon, Head of Investor Relations


+ 44 (0) 7721 413496
 
 




SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
 
Stanford Capital Partners (Joint Broker) 
Patrick Claridge
 John Howes
Bob Pountney 
 
SI Capital (Joint Broker)
Nick Emerson
 


+44 (0) 203 368 3550
 
 
+44 (0) 203 815 8880
 
 
+44 (0) 1483 413500
 
 




4Reliance (Euronext Growth Listing Sponsor)
Jean-Charles Snoy
 
Degroof Petercam (Liquidity Provider)
Erik De Clippel
 
Backstage Communication
Olivier Duquaine
Gunther De Backer


+32 (0) 2 747 02 60
 
 
+32 (0) 2 287 95 34
 
 
 
+32 (0) 477 504 784
+32 (0) 475 903 909
 

















Notes to Editors
 
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. 
 
For additional information about ImmuPharma please visit www.immupharma.com. 
 
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHUVOWRRAUAUAA